GSK Hopes to Lead New Class of Immunotherapies with Merck KGaA Collaboration

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)

Published: 8 Feb-2019

DOI: 10.3833/pdr.v2019.i2.2403     ISSN: 1756-7874

Section: Research & Development



GlaxoSmithKline (GSK) has announced a collaboration with Merck KGaA for the co-development and co-commercialisation of M7824 (bintrafusp alfa), a fusion protein immunotherapy agent that targets two pathways commonly used by cancer cells – transforming growth factor-β (TGF-β) trap and an anti-programmed cell death ligand-1 (PD-L1)...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details